Anjali Advani, MD
Enriched profileStaff Physician, Department of Hematologic Oncology and Blood Disorders; Director, Inpatient Leukemia Program, Taussig Cancer Institute · Cleveland Clinic
Anjali Advani is Staff Physician, Department of Hematologic Oncology and Blood Disorders; Director, Inpatient Leukemia Program, Taussig Cancer Institute at Cleveland Clinic. OpenAlex indexes 629 publications with 14,061 citations (h-index 57); ClinicalTrials.gov lists 16 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Anjali S. Advani, MD, is Staff Physician, Department of Hematologic Oncology and Blood Disorders at Cleveland Clinic (Taussig Cancer Institute). The public record shows 629 publications with 14,061 citations (h-index 57), centered on Hematology. It also documents an investigator role on 16 registered clinical trials, industry payments reported by 9 companies.
- Most recent indexed publication: 2026 · Blood advances
- Top research focus: Hematology
- 16 registered trials on ClinicalTrials.gov
- Open Payments reporting from 9 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 30 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 16 registered studies on ClinicalTrials.gov. The most recent:
- Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia
Sponsor: SWOG Cancer Research Network
- Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
Sponsor: SWOG Cancer Research Network
- Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia
Sponsor: National Cancer Institute (NCI)
Industry payments
Updated 27 Aug 2026
9 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20255 payments
- Syndax Pharmaceuticals, Inc.Program year20252 payments
- PFIZER INC.Program year20245 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
43%Kinase inhibitor34.4%Imatinib Mesylate46%Imbruvica15%Sprycel13%Jakafi11%Gleevec8%Bosulif7%Part D<11 patientsIsocitrate Dehydrogenase 1 Inhibitor4.5%Tibsovo100%Part D<11 patientsDermatology
21.7%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor21.7%Acyclovir100%Part D≥24 patientsNervous system
14%Gabapentinoids7.7%Gabapentin100%Part D<11 patientsOther antidepressants6.2%Mirtazapine100%Part D≥14 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/anjali-advani-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/profile/Anjali-Advani
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
case.edu/cancer/members/member-directory/anjali-s-advani
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →case.edu ↗ - Other
my.clevelandclinic.org/podcasts/cancer-advances/beyond-7-plus-3-redefining-aml-treatment-with-targeted-therapies-and-trials
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →my.clevelandclinic.org ↗ - Other
my.clevelandclinic.org/podcasts/cancer-advances/beyond-chemotherapy-advancements-in-all-treatment
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →my.clevelandclinic.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.clevelandclinic.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.clevelandclinic.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.clevelandclinic.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →providers.clevelandclinic.org ↗
Editorial & leadership roles
journal and society appointments- Member
Southwest Oncology Group (SWOG) Leukemia Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.clevelandclinic.org ↗ - Co-Chair
Data Safety and Monitoring Board committee for clinical trials, Case Comprehensive Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →case.edu ↗ - Member
American Society of Hematology; American Society of Clinical Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.clevelandclinic.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.clevelandclinic.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.clevelandclinic.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.clevelandclinic.org ↗
Secondary affiliations
appointments beyond the home institution- Associate Professor
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →case.edu ↗ - Member
Developmental Therapeutics Program, Case Comprehensive Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →case.edu ↗
Media & interviews
press, podcasts and appearances- Guest
"Beyond Chemotherapy: Advancements in ALL Treatment", Cleveland Clinic Cancer Advances podcast
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →my.clevelandclinic.org ↗ - Guest
"Beyond 7+3: Redefining AML Treatment with Targeted Therapies and Trials", Cleveland Clinic Cancer Advances podcast
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →my.clevelandclinic.org ↗ - Contributing author/interviewee
OncLive (oncology news/video platform)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Samir Kapadia, MD
Cleveland Clinic
Lars Svensson, MD
Cleveland Clinic
Mina Chung, MD
Cleveland Clinic
Gene Barnett, MD
Cleveland Clinic